Pulmonology

Beyond Air® Schedules First Fiscal Quarter 2023 Financial Results Conference Call and Webcast

Retrieved on: 
Wednesday, July 27, 2022
Time, Physician, Hospital, Forward-looking statement, NO, SEC, Union, Nitric oxide, Nontuberculous mycobacteria, Risk, Marketing, COVID-19, PH, Atmosphere of Earth, NTM, Pulmonology, Policy, FDA, Company, Patient, Pulmonary hypertension, Annual report, Urinary tract infection, Pharmaceutical industry

The Company has received FDA approval for its first system, LungFit PH for persistent pulmonary hypertension of the newborn.

Key Points: 
  • The Company has received FDA approval for its first system, LungFit PH for persistent pulmonary hypertension of the newborn.
  • Additionally, Beyond Cancer, an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting.
  • Forward-looking statements include statements about our expectations, beliefs, or intentions regarding our product offerings, business, financial condition, results of operations, strategies or prospects.
  • Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made.

Congressional Delays Mean Lifesaving Health Benefits Hang in the Balance for Veterans Facing Toxic Exposure Issues

Retrieved on: 
Tuesday, July 26, 2022
Storm, Linda, Gulf War, Congress, Sergeant, U.S. Department of Veterans Affairs, Office of Inspector General, Seymour Johnson Air Force Base, Air force, Pond, Canadian Army Veteran Motorcycle Units, Government, Vietnam veteran, House, Religion, Blair Brandt, Asthma, Atmosphere of Earth, Cancer, Spine, Pulmonology, Burn, Review, Disability, Caregiver, Veterans' affairs, Lists of diseases, Soldier, Independently Funded News Consortia, Senate, Letter, Army, Health insurance, Pharmaceutical industry, Veteran

WASHINGTON, July 26, 2022 /PRNewswire/ -- The Independence Fund again endorses the Sergeant First Class Heath Robinson Honoring our PACT Act of 2022, and pleads with the Senate to pass it without amendment, without delay, and before Congress goes into its August recess. The Veteran-serving non-profit submitted a letter of endorsement for the bill co-signed by 13 additional Veteran-serving organizations ahead of Senate reconsideration.

Key Points: 
  • "Toxic exposure has plagued the Veteran community for decades," explains Bob Carey, Executive Vice President of Advocacy and Strategy for The Independence Fund.
  • "More than three million Veterans have symptoms ranging from asthma to unexplained neurological disorders, rare cancers, pulmonary diseases, and more.
  • Our government has allowed them to be on the front lines of exposure to the horrors of toxic exposure without relief for far too long."
  • He has been facing the effects of toxic exposure for more than 6 years, including restrictive lung disease and a new, still-undiagnosed disease in his lungs.

National Jewish Health Ranked a Top Respiratory Hospital by U.S. News & World Report

Retrieved on: 
Tuesday, July 26, 2022
Patient, University, View, University of Colorado Hospital, Elective surgery, Hospital, CEO, World, History, Pulmonology, National Jewish Health, Safety, COVID-19, Chronic obstructive pulmonary disease, Multimedia, Jegs High Performance, News, U.S. News & World Report, Lung, Caregiver, MD, Heart, Adult, Survival, COPD, Medicine, Pneumonia

DENVER, July 26, 2022 /PRNewswire/ -- National Jewish Health has been named a top respiratory hospital for the 26th consecutive year by U.S. News & World Report on its 2022-23 list of best hospitals in the nation. This year National Jewish Health ranked #2 on the list and has held the #1 or #2 position in the publication's pulmonology rankings in all 26 years that pulmonology care has been evaluated.

Key Points: 
  • DENVER, July 26, 2022 /PRNewswire/ -- National Jewish Health has been named a top respiratory hospital for the 26th consecutive year byU.S.
  • News & World Reportreinforces our 123-year history as the leading respiratory care hospital in the nation," said Michael Salem, MD, president and CEO of National Jewish Health.
  • News & World Reporthas ranked National Jewish Health together with its longtime academic affiliate the University of Colorado Hospital.
  • Patients and families come to National Jewish Health from around the world to receive cutting-edge, comprehensive, coordinated care.

SEI Healthcare Releases New Educational Program & Interactive Webinar on AATD

Retrieved on: 
Friday, July 22, 2022
Infection, Division, Knowledge, Diagnosis, University, HCPS, Pleasure, Physician, Lists of diseases, Heidelberg University, AATD, CSL Behring, Guideline, Disease, MD, Patient, Department, Paradigm shift, COPD, Program, Critical Care Medicine (journal), Alpha-1 antitrypsin deficiency, University of Manchester, Medicine, Pharmaceutical industry, Medical device, Medical imaging, Immunity, Pulmonology

SEI Healthcare has recently announced the successful release of an educational program & interactive webinar on alpha-1 antitrypsin deficiency (AATD)

Key Points: 
  • Lewes, Delaware--(Newsfile Corp. - July 22, 2022) - SEI Healthcare, a global, professional Independent Medical Education organization, has announced the successful release of an educational program and interactive webinar on alpha-1 antitrypsin deficiency (AATD), titled "Paradigm Shifts in AATD and Impact on Patient Management".
  • This program included the development of four patient case simulations on a live interactive webinar, which was attended by over 1900 healthcare professionals (HCPs).
  • Further details about this educational program can be found at:
    "An educational project on this topic has proven to be of extreme importance.
  • SEI Healthcare has the pleasure to continue developing educational projects bringing forth strategic insights to optimise outcomes," says Leana Ribeiro, Global Accounts Manager for SEI Healthcare.

Epistemic AI Launches Strategic Collaboration with Cincinnati Children’s Hospital Medical Center

Retrieved on: 
Tuesday, July 19, 2022
Software, Research, Philanthropy, Data Management, Consumer, Technology, Hospitals, Children, Science, Other Technology, Other Philanthropy, Health, People, BEF, Leadership, Research, EAI, Pulmonology, Disease, CEO, Epistemology, Knowledge, Patient, Foundation, Artificial intelligence, Hospital, Bacteria, Drug discovery, Technology, AI, Cincinnati, Mucus, Faculty, Human, Advocacy, NFL, Respiratory system, Cincinnati Children's Hospital Medical Center, Health, CF, Diagnosis, CFTR, Respiratory disease, Boomer Esiason, Partnership, MVP, Intelligence, Biomedical Research, Awareness, Pharmaceutical industry, Medical device, Cystic fibrosis

Epistemic AI (EAI) announced that through its collaboration with the Boomer Esiason Foundation (BEF), and the leadership of Dr. Raouf Amin at Cincinnati Childrens Hospital Medical Center, that the Cincinnati Childrens Division of Pulmonary Medicine will use the EAI platform to augment and accelerate their research in Cystic Fibrosis (CF) and respiratory disease.

Key Points: 
  • Epistemic AI (EAI) announced that through its collaboration with the Boomer Esiason Foundation (BEF), and the leadership of Dr. Raouf Amin at Cincinnati Childrens Hospital Medical Center, that the Cincinnati Childrens Division of Pulmonary Medicine will use the EAI platform to augment and accelerate their research in Cystic Fibrosis (CF) and respiratory disease.
  • According to Stefano Pacifico, CEO, and co-founder of Epistemic AI, this confirms EAIs commitment to support clinical research in cystic fibrosis.
  • Cincinnati Childrens Hospital has been a long-standing partner of the Foundation, and we are thrilled to reaffirm our commitment to the Hospital and CF Center by providing cutting edge tools to advance their work."
  • Epistemic AI works with academia, foundations, and biopharma companies to help advance their efforts in R&D, drug discovery, clinical trials, and commercialization.

AMN Healthcare Report: Orthopedic Surgeons Offered the Highest Physician Starting Salary at $565,000

Retrieved on: 
Monday, July 18, 2022
Surgery, Human Resources, Hospitals, Consulting, Professional Services, Practice Management, Other Health, Managed Care, Radiology, Health, NPS, Leadership, PAS, Crna, Gastroenterology, AMN, AMCS, Patient, Academic health science centre, Hospital, Radiology, Annual report, Incentive, Neurology, Urology, NYSE, Doctor of Nursing Practice, Physician, Oncology, Pulmonology, Telehealth, Orthopedic surgery, Ageing, Industry, COVID-19, Company, Practitioner, Efficiency, Community, Credentialing, Elective surgery, School, Lists of diseases, Population, Medicine, Pharmaceutical industry

Orthopedic surgeons are offered the highest average starting salary among physicians and advanced practice professionals, according to an annual report from AMN Healthcare and its physician search division, Merritt Hawkins.

Key Points: 
  • Orthopedic surgeons are offered the highest average starting salary among physicians and advanced practice professionals, according to an annual report from AMN Healthcare and its physician search division, Merritt Hawkins.
  • Demand for physicians, and the salaries they are offered, have rebounded dramatically from the height of COVID-19, said Tom Florence, president of physician permanent placement for AMN Healthcare.
  • AMN Healthcare is the leader and innovator in total talent solutions for healthcare organizations across the nation.
  • With insights and expertise, AMN Healthcare helps providers optimize their workforce to successfully reduce complexity, increase efficiency and improve patient outcomes.

SINOVAC COVID-19 Vaccine Is Authorized for Emergency Use in Kids Aged 3-5 In Brazil

Retrieved on: 
Thursday, July 14, 2022
COVID-19, Research, Infectious Diseases, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, COVID-19, Influenza A virus subtype H1N1, Program, Pulmonology, Vaccine, H5N1, Infection, HFMD, SBP, WHO, Vaccination, Company, Hepatitis A, R, Mumps, Foot-and-mouth disease virus, Ageing, Brazilian Association of Investigative Journalism, Minor, SBI, Chickenpox, Instituto Butantan, Sinovac Biotech, Research, Association, CoronaVac, EV71, Streptococcus, To Brazil!, NASDAQ, Polio, Pharmaceutical industry, Brazilian Health Regulatory Agency, COVID-19, Research, Infectious Diseases, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science

This authorization was given under comprehensive evaluations based on analysis results from all available data on the vaccine and its use in children.

Key Points: 
  • This authorization was given under comprehensive evaluations based on analysis results from all available data on the vaccine and its use in children.
  • To assist Anvisa in evaluating the vaccine, the experts from the above institutions had access to technical materials and research data on the vaccine.
  • CoronaVac has been authorized for emergency use for adults in Brazil since January 17, 2021.
  • SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.

AdaptHealth Corp. Announces Second Quarter 2022 Earnings Release Date and Conference Call

Retrieved on: 
Wednesday, July 13, 2022
Medical Supplies, Health, Medical Devices, Telemedicine, Virtual Medicine, Health Technology, Other Health, General Health, Diabetes, Obstructive sleep apnea, Pulmonology, Interest, PAP, Company, Patient, Oxygen, Incontinence, Stoma, CPAP, HME, NASDAQ, Solution, Hospital, Medicare, Medicaid

AdaptHealth Corp. (NASDAQ: AHCO) (AdaptHealth or the Company), a national leader in providing patient-centered healthcare-at-home solutions including home medical equipment, medical supplies, and related services, will release its second quarter 2022 financial results before the opening of the financial markets on Tuesday, August 9, 2022.

Key Points: 
  • AdaptHealth Corp. (NASDAQ: AHCO) (AdaptHealth or the Company), a national leader in providing patient-centered healthcare-at-home solutions including home medical equipment, medical supplies, and related services, will release its second quarter 2022 financial results before the opening of the financial markets on Tuesday, August 9, 2022.
  • ET to discuss the results and business activities with analysts and investors.
  • Interested parties may participate in the call by dialing:
    Following the live call, a replay will be available for six months on the Company's website, www.adapthealth.com under "Investor Relations."
  • AdaptHealth is a national leader in providing patient-centered healthcare-at-home solutions including home medical equipment, medical supplies, and related services.

Small Molecule API Market Size Worth $282.50 Billion by 2030: Grand View Research, Inc.

Retrieved on: 
Tuesday, July 12, 2022
Molecule, NCBI, Oncology, Lonza, Acquisition, Synthetic, Novasep, SAN, Government, COVID-19, CDMO, CAGR, FDA, Revenue, API, Adoption, CNS, Growth, Industry, USD, Fine chemical, Endocrinology, Biotechnology, Pulmonology

SAN FRANCISCO, July 12, 2022 /PRNewswire/ -- The global small molecule API market size is expected to reach USD 282.50 billion by 2030, expanding at a CAGR of 5.44% during the forecast period, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, July 12, 2022 /PRNewswire/ -- The global small molecule API market size is expected to reach USD 282.50 billion by 2030, expanding at a CAGR of 5.44% during the forecast period, according to a new report by Grand View Research, Inc.
  • The increasing number of new pharmaceuticals entering the market is creating a lucrative opportunity for key players.
  • The synthetic small molecule API segment is largely driven by the presence of small companies and CDMOs that cater to the changing requirements of the industry.
  • Grand View Research has segmented the global small molecule API market based on type, manufacturer, application, and region:
    Small Molecule API Type Outlook (Revenue, USD Billion, 2018 - 2030)
    Small Molecule API Manufacturer Outlook (Revenue, USD Billion, 2018 - 2030)
    Small Molecule API Application Outlook (Revenue, USD Billion, 2018 - 2030)

RS Biotherapeutics Reports Positive Results From Proof-of-Concept Trial for First Investigational Compound

Retrieved on: 
Monday, July 11, 2022
ECS, Safety, Cytokine, COPD, Dexamethasone, IL6, Inflammation, Entrepreneurship, Lung, Marshall University, Pulmonology, SARS-COV-2, Asthma, Shikimate pathway, Degenerative disease, Endocannabinoid system, LPS, Cystic fibrosis, Bronchitis, GLOBE, Research, Immune system, Escherichia coli, RS, Liquor, Pharmaceutical industry, Synthon

RS BioTherapeutics conducted the study in conjunction with RSBT-001 development partner, Synthonics, Inc., and Marshall University using a mouse model of pulmonary inflammation.

Key Points: 
  • RS BioTherapeutics conducted the study in conjunction with RSBT-001 development partner, Synthonics, Inc., and Marshall University using a mouse model of pulmonary inflammation.
  • Anti-inflammatory response was determined by measuring a series of cytokines known to be highly expressed in response to pulmonary inflammation.
  • RS BioTherapeutics has initiated a second study with Marshall to further evaluate the impact of RSBT-001 on pulmonary inflammation.
  • Founded by experts in pulmonary diseases and the endocannabinoid system, RS BioTherapeutics is a wholly owned subsidiary of Real Science Holdco LLC.